Used in immunotherapy research to modulate T-cell activity by blocking the LAG-3 receptor, which plays a role in immune checkpoint pathways. This antibody serves as a reference standard in the development of biologics targeting LAG-3 for cancer treatment, particularly in combination with other checkpoint inhibitors like anti-PD-1/PD-L1 therapies. It is utilized in binding assays, functional studies, and biosimilar characterization to ensure consistency and efficacy in therapeutic antibody development.